Precision-health AI platform spun out of Alphabet/Google X — runs the Verily Pre clinical-research platform and Onduo virtual-care services
Verily (formerly Google Life Sciences, renamed Verily in December 2015) is a precision-health AI company that began as a research unit inside Google X and was spun into an Alphabet subsidiary in 2015 under founding CEO Andrew Conrad. Stephen Gillett (ex-Symantec / Best Buy) took over as CEO in 2023. In March 2026 the company raised a $300M strategic round led by Series X Capital with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and others — a recapitalization that left Alphabet as a significant minority (no longer controlling) investor, effectively spinning Verily out as a stand-alone company. Headquartered in Dallas, TX since August 2024 (moved from South San Francisco). Operates the Verily Pre clinical-research platform, Onduo virtual chronic-care, Project Baseline, and Liftware; recently signed partnerships with Samsung Galaxy Watch and Salesforce Agentforce Health. 2022 revenue of $559M against a $568M operating loss; total raised across Series A-C (Silver Lake, Temasek, SoftBank) plus the 2026 recap is ~$3.3B. Valuation reportedly written down ~80% from 2022 peak (~$23B) per The Information and Business Insider, putting the post-recap value in the $4-5B range.
Healthcare📍 Dallas, TXFounded 2015
Current Valuation
$5.0B
as of 2026-Q1
UNICORN
QL Price
$5.0B
0% vs last round
QuantLogix's current estimate for Verily, published 2026-10-07 — in line with the last disclosed round of $5.0B (2026-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$5.0B
2026-Q1
weight 0.7
How this price has held up
No round has priced for Verily since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Verily, 2026-10-07 (ccb05226cfec1c96).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Verily going public?
No. Verily has no imminent IPO plans on record. It is still private.
What is Verily's valuation in 2026?
Verily is valued at $5.0B as of 2026-Q1, set by its Strategic recapitalization ($300M, Mar 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Verily filed an S-1?
No public S-1 is on file for Verily.
Who are Verily's investors?
Verily's investors include Series X Capital, Alphabet (minority post-2026), UCHealth, University of Colorado Anschutz, Silver Lake, Temasek and 1 more.
How much has Verily raised?
Verily has raised $3.3B in total, most recently a Strategic recapitalization of $300M in Mar 2026.
Is Verily publicly traded — can you buy Verily stock?
No. Verily is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Verily on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Stephen Gillett
Founded
2015
HQ
Dallas, TX
Employees
~1100
Total Raised
$3.3B
Est. Revenue
$559M (2022-Q4)
Growth
Restructuring — revenue $559M (2022) with $568M operating loss; post-2026 recap is a relaunch under Series X Capital
Last Round
Strategic recapitalization — $300M (Mar 2026) · Lead: Series X Capital
IPO Status
no imminent plans
Fundraising Status
Strategic recapitalization · $300M · 7 mo ago
no imminent plansTotal raised $3.3B
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Strategic recapitalization
$300M
Mar 2026
Series X Capital
—
Vertical Intelligence — AI / ML
No verified Hugging Face organization found for Verily — no attributable open-model footprint. Closed-weights labs are common; this is a distribution signal, not a capability judgment.
Checked huggingface.co as of 2026-10-04. Re-checked weekly.
Talent Signal
Hiring trend
▲ Hiring uptrend
+17% vs 2026-08
Open roles
76
via workday
Product-build share
68%
engineering, research, product, design
Trajectory
expanding
heavy product build — 68% of open roles are product-building functions (engineering/research/product) — 34 of 76 open roles are engineering.
No tracked executive churn; open roles trending up.
Counted from Verily's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Andrew Conrad
Investors
Series X Capital · Alphabet (minority post-2026) · UCHealth · University of Colorado Anschutz · Silver Lake · Temasek · SoftBank Vision Fund
Products
Verily Pre Platform (precision-health AI for life-sciences research)
Onduo (virtual chronic-disease care)
Liftware (assistive eating utensils)
Project Baseline (longitudinal health study)
Competitors
Tempus AI · Flatiron Health (Roche) · Komodo Health · Truveta · OneStudyTeam (CRO infrastructure) · Iqvia
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q1. Refreshed quarterly.